Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
An announcement from GlaxoSmithKline ( (GB:GSK) ) is now available.
GSK has announced the appointment of Dr. Gavin Screaton as a Non-Executive Director, effective May 1, 2025. Dr. Screaton, an expert in immunology and infectious diseases, will replace Dr. Jesse Goodman, who is retiring after nine years of service. Dr. Screaton’s extensive experience in public health and his current role at the University of Oxford will enhance GSK’s expertise in its core scientific areas. This strategic move is expected to strengthen GSK’s board as it continues to focus on its biopharmaceutical endeavors, potentially impacting its positioning in the industry and its stakeholders.
More about GlaxoSmithKline
GSK is a global biopharma company focused on uniting science, technology, and talent to advance disease prevention and treatment.
YTD Price Performance: 6.76%
Average Trading Volume: 7,365,639
Technical Sentiment Consensus Rating: Sell
Current Market Cap: £58.9B
Find detailed analytics on GSK stock on TipRanks’ Stock Analysis page.
